![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 2 of 2. This is the beginning of the thread.
Posted by PeterMartin on July 15, 2017, at 21:18:42
A few months ago Jazz pharmaceuticals released positive phase 3 results for their narcolepsy drug jzp-110 (formally ADX-N05). According to a few articles they'll be submitting it for FDA approval in late 2017.
Has anyone followed this drug or have info on it? Could it possibly be helpful for mood disorders or sleep issues caused by psych meds?
Thanks for any discussion.
One article:
Posted by SLS on July 16, 2017, at 8:57:33
In reply to Any thoughts on JZP-110 (DNRI / NDA late 2017), posted by PeterMartin on July 15, 2017, at 21:18:42
Hi, Peter.
> Has anyone followed this drug or have info on it? Could it possibly be helpful for mood disorders or sleep issues caused by psych meds?
>
> Thanks for any discussion.Thanks for discovering and sharing!
I'm sure you are aware that this drug is a reuptake inhibitor of both dopamine and norepinephrine. It reminds me of nomifensine (Merital) in this respect. Nomifensine was a good antidepressant. Lots of people found it to be the only medication to successfully treat their depression. Unfortunately, the drug was withdrawn from market by the drug company due to a few reports of hemolytic anemia. There was some debate as to whether this was really necessary. I tried nomifensine. I experienced a brief partial response to it.
If I weren't taking a MAOI (Parnate), I would consider this drug for myself. I might switch if it emerges as a great antidepressant.
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.